The intra-individual variability of faecal calprotectin: A prospective study in patients with active ulcerative colitis
- 1 July 2014
- journal article
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 9 (1) , 26-32
Abstract
Leukocyte-derived proteins in faeces, especially calprotectin, are increasingly used to assess disease activity in ulcerative colitis. The objectives of the present study were to assess the importance of factors related to the stool sampling procedure. For 2 days, patients with active ulcerative colitis collected two stool samples at each bowel movement. The time of defecation, consistency and presence of blood were self-recorded in a diary. The variability in the concentrations of calprotectin during the day and between two consecutive days was assessed, as was the stability of calprotectin concentrations in samples stored at room temperature. Altogether, 18 patients collected 287 stool samples. The intraclass correlation coefficient in pairs of samples from 132 bowel movements was 0.79 (95% CI 0.48-0.90). The median individual coefficient of variation in samples collected during the same day was 52% (4-178). There was a correlation between the level of calprotectin and the time between bowel movements (r = 0.5; p = 0.013). After 3 days at room temperature the calprotectin concentrations in stool samples were unchanged, but after 7 days a significant (p < 0.01) decrease was found (mean 28%; 95% CI 0.10-0.47). The present data reveal a great variability in the concentrations of calprotectin in stool samples collected during a single day. Since the levels of calprotectin increased with longer time between the bowel movements, it seems most appropriate to analyse stool from the first bowel movement in the morning. Moreover, storage of stool samples at room temperature for more than 3 days is not advisable.Keywords
This publication has 25 references indexed in Scilit:
- Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 1: Definitions and diagnosisJournal of Crohn's and Colitis, 2012
- Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel diseaseInflammatory Bowel Diseases, 2012
- Discriminating IBD from IBS: Comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodiesInflammatory Bowel Diseases, 2008
- Crohnʼs disease activity assessed by fecal calprotectin and lactoferrin: Correlation with Crohnʼs disease activity index and endoscopic findingsInflammatory Bowel Diseases, 2008
- Faecal calprotectin in the assessment of Crohn's disease activityQJM: An International Journal of Medicine, 2005
- Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factorsAmerican Journal of Gastroenterology, 2002
- A simple method for assessing intestinal inflammation in Crohn's diseaseGut, 2000
- Assessment of Disease Activity in Ulcerative Colitis by Faecal Calprotectin, a Novel Granulocyte Marker ProteinDigestion, 1997
- Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.BMJ, 1989
- Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative ColitisNew England Journal of Medicine, 1987